Regulatory Clearance and Approval of Therapeutic Protocols of Transcranial Magnetic Stimulation for Psychiatric Disorders

Non-invasive brain stimulation techniques (NIBS) have been widely used in both clinical and research contexts neuropsychiatry. They are safe well-tolerated, making NIBS an interesting option for application different settings. Transcranial magnetic (TMS) is one of these strategies. It uses electromagnetic pulses focal modulate ion neuronal activity cortical regions. When applied repeatedly (repetitive transcranial stimulation—rTMS), they thought to induce long-lasting neuroplastic effects, proposed be a therapeutic mechanism rTMS, with efficacy safety initially demonstrated treatment-resistant depression (TRD). Since then, many rTMS treatment protocols emerged other difficult treat psychiatric conditions. Moreover, multiple studies, including large multi-center trials several meta-analyses, confirmed its neuropsychiatric disorders, resulting evidence-based guidelines recommendations. Currently, cleared by regulatory agencies the TRD, comorbid anxiety obsessive compulsive disorder, substance use such as smoking cessation. Importantly, current supports potential future syndromes, negative symptoms schizophrenia post-traumatic stress disorder. More precise knowledge formal indications psychiatry critical enhance decision this area.